Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H4Cl3IO |
Molecular Weight | 361.3911 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(#CI)COc1cc(c(cc1Cl)Cl)Cl
InChI
InChIKey=CTETYYAZBPJBHE-UHFFFAOYSA-N
InChI=1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2
Haloprogin is an active synthetic antifungal and antimonilial agent that was effective in the treatment of superficial fungal and monilial infections of the skin. Because of these two basic therapeutic effects, haloprogin was especially useful in the treatment of infections when the identity of the specific causative organism had not been established or is being determined. Studies in-vitro demonstrated antifungal, antimonilial and antibacterial activity. It was shown to demonstrate marked in-vitro activity against Staphylococcus and Streptococcus. Haloprogin is no longer available in the US.
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5422306
Curator's Comment:: Preliminary data on the antifungal properties of haloprogin, originally identified as M1028, were reported by Seki and associates in 1964.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Haloprogin: a topical antifungal agent. | 1970 May |
|
Haloprogin: mode of action studies in Candida albicans. | 1974 Sep |
|
In vitro activity of ME1401, a new antifungal agent. | 1986 Nov |
|
Synthesis and microbiological activity of some novel 5- or 6-methyl-2-(2,4-disubstituted phenyl) benzoxazole derivatives. | 1998 May 30 |
|
(E)-2-{(2-Hydroxy-naphthalen-1-yl)methyl-ene}hydrazinecarboxamide. | 2009 Apr 25 |
|
1-(5-Carboxy-pent-yl)-2,3,3-trimethyl-3H-indol-1-ium bromide monohydrate. | 2009 Dec 16 |
|
2,4-Dichloro-1-[1-(2,4-dichloro-benz-yl-oxy)eth-yl]benzene. | 2009 Dec 16 |
|
Gabapentin-lactum-chloranilic acid (1/1). | 2009 Dec 16 |
|
11-[3-(Dimethyl-amino)prop-yl]-6,11-dihydro-dibenzo[b,e]thiepin-11-ol. | 2009 Dec 16 |
|
6,11-Dihydro-dibenz[b,e]oxepin-11-one. | 2009 Dec 16 |
|
N-(3,4-Dichloro-phen-yl)-3-oxo-butanamide. | 2009 Dec 4 |
|
(E)-2-[(2-Hydr-oxy-5-nitro-phen-yl)iminiometh-yl]phenolate. | 2009 Feb 11 |
|
(E)-2-[(2-Hydr-oxy-5-nitro-phen-yl)iminiometh-yl]-4-nitro-phenolate. | 2009 Jan 14 |
|
3-(2,6-Dioxopiperidin-3-yl)-3-aza-bicyclo-[3.2.0]heptane-2,4-dione. | 2009 Jan 28 |
|
Propiverinium picrate. | 2009 Jul 1 |
|
2-Amino-5-nitro-phenyl 2-chloro-phenyl ketone. | 2009 Jul 18 |
|
Violacein-producing Collimonas sp. from the sea surface microlayer of costal waters in Trøndelag, Norway. | 2009 Nov 12 |
|
1-(2-Methyl-5-nitro-phenyl)guanidinium picrate. | 2009 Oct 17 |
|
Environmental stresses inhibit splicing in the aquatic fungus Blastocladiella emersonii. | 2009 Oct 29 |
|
2-Bromo-N'-[(2Z)-butan-2-yl-idene]-5-methoxy-benzohydrazide. | 2009 Oct 31 |
|
2-Amino-4-meth-oxy-6-methyl-pyrimidin-1-ium picrate. | 2010 Apr 28 |
|
5,7-Dimethyl-2,3-dihydro-1H-1,4-diazepin-4-ium picrate. | 2010 Apr 28 |
|
7-(4-Bromo-phen-yl)-9-phenyl-7H-pyrrolo[3,2-e]tetra-zolo[1,5-c]pyrimidine. | 2010 Feb 10 |
|
6-{[(Benz-yloxy)carbon-yl]-oxy}-2-methyl-hexa-hydro-pyrano[3,2-d][1,3]dioxin-7,8-diyl bis-(chloro-acetate). | 2010 Feb 10 |
|
7-(4-Chloro-phen-yl)-9-phenyl-7H-pyrrolo[3,2-e]tetra-zolo[1,5-c]pyrimidine. | 2010 Feb 13 |
|
Desipramine hydro-chloride: a non-merohedrally twinned structure. | 2010 Feb 20 |
|
(E)-2-Acetyl-4-[(3-methyl-phenyl-)diazen-yl]phenol: an X-ray and DFT study. | 2010 Feb 6 |
|
Dibenzo[b,e]thiepin-11(6H)-one. | 2010 Jan 13 |
|
N-(5-Amino-2-methyl-phen-yl)-4-(3-pyri-dyl)-pyrimidin-2-amine. | 2010 Jan 13 |
|
Chlorimipraminium picrate. | 2010 Jan 13 |
|
1-(1,3-Benzodioxol-5-yl)ethanone. | 2010 Jan 16 |
|
Trimipraminium maleate. | 2010 Jan 16 |
|
N,N'-Bis-[(E)-2-fluoro-benzyl-idene]-1-(2-fluoro-phen-yl)methane-diamine. | 2010 Jan 23 |
Sample Use Guides
1% cream or solution applied liberally to the affected area twice daily
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/5422306
The in vitro fungistatic concentrations were determined by a serial dilution method using Sabouraud's liquid medium. The concentration of drug tested ranged from 0.19 to 100 ug/ml. All tubes were inoculated with approximately 10(5) viable macrospores obtained by washing the surface of a 14-day slant culture of the test dermatophyte with Sabouraud's liquid medium and diluting to the desired concentration. The inoculated assay tubes were incubated at room temperature (28 Celsius) for 7 days and examined for visible growth.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
||
|
WHO-ATC |
D01AE11
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
||
|
NCI_THESAURUS |
C28394
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
||
|
CFR |
21 CFR 333.210
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
||
|
WHO-VATC |
QD01AE11
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1355
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
M1184
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | Merck Index | ||
|
C65842
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
DB00793
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
2263
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
3561
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
212-286-6
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
26422
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | RxNorm | ||
|
AIU7053OWL
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
777-11-7
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
C100276
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
SUB08008MIG
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
CHEMBL1289
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
HALOPROGIN
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY | |||
|
777-11-7
Created by
admin on Sat Jun 26 14:44:41 UTC 2021 , Edited by admin on Sat Jun 26 14:44:41 UTC 2021
|
PRIMARY |
ACTIVE MOIETY